Mitral Valve Repair — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Mitral valve repair is an open cardiac surgical procedure to correct a dysfunctional mitral valve — the bicuspid valve separating the left atrium from the left ventricle — by reshaping, reconstructing, or reinforcing its native components rather than replacing it with a prosthetic (mechanical or bioprosthetic) valve. The mitral valve apparatus consists of two leaflets (anterior and posterior), the annulus (fibrous ring), chordae tendineae (fibrous cords connecting the leaflets to the papillary muscles), and the papillary muscles. Mitral regurgitation (MR) — the backward leaking of blood from the left ventricle into the left atrium during systole — is the most common indication, most frequently caused by degenerative disease (leaflet prolapse or flail leaflet from ruptured chordae in Barlow's disease or fibroelastic deficiency). Mitral repair preserves the patient's own valve tissue, maintains left ventricular geometry and function by preserving the subvalvular apparatus, avoids the need for lifelong anticoagulation (unlike mechanical valve replacement), and offers superior long-term durability compared to prosthetic replacement in experienced repair centres. ESC/EACTS and AHA/ACC guidelines strongly recommend mitral valve repair over replacement for degenerative MR when repair is technically feasible, targeting repair rates exceeding 95% for experienced surgeons.

Mitral valve repair is indicated for severe mitral regurgitation meeting guideline-based criteria for intervention. The AHA/ACC 2021 Valvular Heart Disease Guidelines recommend surgery for: symptomatic severe MR (New York Heart Association Class II–IV symptoms) with preserved ejection fraction (LVEF >60%); asymptomatic severe MR with evidence of left ventricular dysfunction (LVEF 30–60%, LVESD ≥40 mm); asymptomatic severe MR with preserved LV function in patients in whom durable repair is highly likely (>95% probability) at an experienced centre; new-onset atrial fibrillation or pulmonary hypertension (resting PASP >50 mmHg) from severe MR; and severe MR in the setting of other cardiac surgery (CABG, aortic valve replacement). Repair is the strongly preferred approach for degenerative disease with posterior leaflet prolapse (85–98% repairability), anterior leaflet prolapse (75–90% repairability at experienced centres), and bileaflet prolapse (80–90%). Rheumatic MR has lower repairability and higher re-repair rates due to ongoing leaflet fibrosis and scarring. Functional MR (from dilated cardiomyopathy) may be addressed with annuloplasty ring but has less durable outcomes. Patients with severe LV dysfunction (LVEF <30%) or severe irreversible pulmonary hypertension have higher operative risk and may require specialist multi-disciplinary assessment.

Mitral valve repair is performed under general anaesthesia. Standard approach is a median sternotomy (breastbone division), though right lateral thoracotomy and video-assisted thoracoscopic (VATS) approaches are used at high-volume minimally invasive centres. Cardiopulmonary bypass (CPB) is established with cannulation of the aorta and right atrium. The aorta is cross-clamped and cardioplegia (cold potassium-rich solution) is administered into the coronary ostia to arrest the heart and provide myocardial protection. The left atrium is opened behind the inter-atrial groove (transseptal approach is an alternative). The mitral valve is inspected systematically using a saline injection test (identifying leaflet prolapse and leaflet coaptation deficiency). Repair techniques are tailored to the specific pathology: posterior leaflet prolapse is addressed by leaflet resection (quadrangular or triangular resection), sliding plasty, or artificial chordae tendineae (PTFE neochordae, polytetrafluoroethylene GoreTex sutures) to the papillary muscle; anterior leaflet prolapse by PTFE neochordae or chordal transfer from posterior leaflet; annular dilatation by ring annuloplasty (implantation of a rigid or flexible Carpentier-Edwards or Medtronic ring of appropriate size to restore annular geometry and support leaflet coaptation). Competence of the repair is confirmed intraoperatively by saline injection test and intraoperative transoesophageal echocardiography (TOE) before weaning from CPB.

The procedure is performed in an appropriately equipped facility by experienced specialist clinicians. Prior to commencement, the patient undergoes pre-procedural assessment including vital signs measurement, review of relevant investigations, and confirmation of informed consent. Intravenous access is established and monitoring equipment including ECG, pulse oximetry, and blood pressure monitoring is applied.

The procedural site is prepared according to aseptic technique standards. Anaesthesia or analgesia is administered as appropriate for the specific procedure and patient needs, ranging from local anaesthesia for minor procedures to regional or general anaesthesia for more complex interventions.

The procedure is performed under direct visualisation or image guidance as appropriate. Key technical steps are executed with attention to anatomical landmarks and patient safety parameters. Haemostasis is achieved and confirmed before completion. Post-procedural assessment includes clinical evaluation of the immediate result, complication surveillance, and documentation of the procedure.

Recovery room monitoring continues until the patient meets defined discharge criteria. Written post-procedural instructions covering activity restrictions, wound care, medication management, and symptoms requiring urgent review are provided before discharge.

Mitral valve repair at experienced centres achieves freedom from reoperation in over 90% of patients at 10 years for degenerative mitral regurgitation, with operative mortality less than 1% for elective isolated procedures. These outcomes are substantially superior to mitral valve replacement: freedom from reoperation for repair is 90% vs. 70–75% for bioprosthesis at 10 years (accounting for structural valve deterioration requiring re-replacement); avoidance of lifelong anticoagulation with its bleeding risks (mechanical valve) or prosthetic degeneration (bioprosthesis). Repair preserves the subvalvular apparatus (chordae and papillary muscles) maintaining left ventricular systolic function, geometry, and synchrony — a benefit lost with complete excision of the native valve during replacement. Echocardiographic studies demonstrate superior post-operative ejection fraction and lower rates of LV dysfunction after repair vs. replacement. The AHA/ACC guidelines and Carpentier repair-or-replace decision studies consistently show superior 10- and 15-year survival with repair. Patient-reported outcomes include significant improvement in exercise tolerance, dyspnoea, and functional class within 3–6 months of successful repair.

Mitral valve repair at experienced high-volume centres carries excellent safety: operative mortality for elective isolated mitral repair is less than 1% (compared to 2–3% for replacement). Stroke occurs in 1–2% and is related to cardiopulmonary bypass, aortic manipulation, and air embolism — mitigated by meticulous de-airing techniques. Atrial fibrillation (AF) is the most common post-operative complication, affecting 30–40% of patients in the first 72 hours; most convert to sinus rhythm within 6 weeks with beta-blockers and, if persistent, cardioversion. Renal failure requiring temporary haemofiltration occurs in 1–3%. Sternal wound infection (mediastinitis) is rare (<1%) but serious, requiring debridement, irrigation, and prolonged antibiotic therapy. Intraoperative conversion to valve replacement occurs in approximately 5% of planned repairs when the tissue quality or anatomy prevents durable repair (rheumatic disease, severely calcified annulus, residual regurgitation on TOE). Repair failure — residual or recurrent MR detected on post-operative echocardiography — requiring reoperation occurs in less than 5% at 10 years for degenerative disease at expert centres. Haemopericardium from post-cardiac surgery inflammatory pericarditis (Dressler's syndrome) occurs in 5–10% and is managed with NSAIDs or colchicine.

After 1–2 days in the cardiac intensive care unit (ICU), patients are transferred to the cardiac surgical ward for 4–5 days, targeting a total hospital stay of 5–7 days. Temporary epicardial pacing wires and chest drains are removed on day 1–2. Anticoagulation with warfarin (target INR 2.0–3.0) is started for 3 months after repair to protect against thromboembolism from the annuloplasty ring and any post-operative AF — this is then discontinued if sinus rhythm is maintained and no ring-prosthetic material requires ongoing anticoagulation. A sternotomy (median) heals over 6–8 weeks; during this period, lifting more than 5 kg, pushing, and pulling should be avoided to prevent sternal wound complications. Driving is prohibited for 6 weeks after sternotomy. Cardiac rehabilitation commences at 4–6 weeks post-surgery with a supervised exercise programme improving functional capacity and confidence. Return to sedentary work at 4–6 weeks; physically demanding work at 8–12 weeks. Echocardiography at 6–8 weeks confirms repair durability and valve function; annual echocardiography thereafter monitors for recurrent MR. Dental procedures should be preceded by antibiotic prophylaxis for 6 months after repair (NICE guideline NG184).